SPIRITT (STUDY 20060141): A RANDOMISED PHASE 2 STUDY OF FOLFIRI WITH EITHER PANITUMUMAB (pmab) OR BEVACIZUMAB (bev) AS 2ND-LINE TREATMENT (tx) IN PATIENTS (pts) WITH WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (mCRC)

被引：0
|
作者：
Hecht, J. R. [1 ]
Cohn, A. [2 ]
Dakhil, S. [3 ]
Saleh, M.
Cline-Burkhardt, M. [4 ]
Piperdi, B. [5 ]
Tian, Y. [6 ]
Go, W. [6 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Rocky Mt Canc Ctr, Denver, CO USA
[3] Canc Ctr Kansas, Liberal, KS USA
[4] US Oncol, Austin, TX USA
[5] Montefiore Med Ctr, New York, NY USA
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [31] Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT
    Peeters, Marc
    Price, Timothy Jay
    Kim, Tae Won
    Li, Jin
    Cascinu, Stefano
    Ruff, Paul
    Suresh, Attili Venkatasatya
    Thomas, Anne L.
    Tjulandin, Sergei
    Zhang, Kathy
    Sidhu, Roger
    Murugappan, Swaminathan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second -line treatment (tx) of metastatic colorectal cancer (mCRC)
    Sobrero, Alberto F.
    Peeters, Marc
    Price, Timothy Jay
    Hotko, Yevhen
    Cervantes-Ruiperez, Andres
    Ducreux, Michel
    Andre, Thierry
    Chan, Emily
    Lordick, Florian
    Tian, Ying
    Sidhu, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] RANDOMIZED PHASE 3 STUDY OF PANITUMUMAB (PMAB) WITH FOLFIRI COMPARED TO FOLFIRI ALONE AS SECOND-LINE TREATMENT (TX) FOR METASTATIC COLORECTAL CANCER (MCRC): SECONDARY ENDPOINT RESULTS
    Peeters, M.
    Price, T.
    Hotko, Y.
    Cervantes, A.
    Ducreux, M.
    Andre, T.
    Chan, E.
    Lordick, F.
    Rong, A.
    Gansert, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 15 - 15
  • [34] KRAS/NRAS AND BRAF MUTATIONS IN THE 20050181 STUDY OF PANITUMUMAB plus FOLFIRI FOR THE 2ND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: UPDATED ANALYSIS
    Peeters, M.
    Oliner, K.
    Price, T.
    Cervantes, A.
    Sobrero, A.
    Ducreux, M.
    Hotko, Y.
    Andre, T.
    Chan, E.
    Lordick, F.
    Punt, C.
    Strickland, A.
    Wilson, G.
    Ciuleanu, T.
    Roman, L.
    Van Cutsem, E.
    Yu, H.
    Jung, A. S.
    Sidhu, R.
    Patterson, S.
    ANNALS OF ONCOLOGY, 2014, 25 : 5 - 5
  • [35] Efficacy of Panitumumab Plus FOLFIRI Versus FOLFIRI Alone in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC) Treated With Prior Oxaliplatin or Bevacizumab Regimens: Results From 20050181
    Price, T.
    Peeters, M.
    Strickland, A.
    Ciuleanu, T. E.
    Scheithauer, W.
    O'Reilly, S.
    Keane, M.
    Spigel, D.
    Tian, Y.
    Kartik, K.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S431 - S432
  • [36] A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
    Garrido-Laguna, I.
    McGregor, K. A.
    Wade, M.
    Weis, J.
    Gilcrease, W.
    Burr, L.
    Soldi, R.
    Jakubowski, L.
    Davidson, C.
    Morrell, G.
    Olpin, J. D.
    Boucher, K.
    Jones, D.
    Sharma, S.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1257 - 1264
  • [37] A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
    I. Garrido-Laguna
    K. A. McGregor
    M. Wade
    J. Weis
    W. Gilcrease
    L. Burr
    R. Soldi
    L. Jakubowski
    C. Davidson
    G. Morrell
    J. D. Olpin
    K. Boucher
    D. Jones
    S. Sharma
    Investigational New Drugs, 2013, 31 : 1257 - 1264
  • [38] Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST)
    Price, T. J.
    Sobrero, A. F.
    Wilson, G.
    Van Cutsem, E.
    Aleknaviciene, B.
    Zaniboni, A.
    Hartmann, J. T.
    Tian, Y.
    Gansert, J. L.
    Peeters, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
    Stintzing, S.
    Jung, A.
    Rossius, L.
    Modest, D. P.
    von Weikersthal, L. Fischer
    Decker, T.
    Moehler, M.
    Scheithauer, W.
    Kirchner, T.
    Heinemann, V.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S8 - S9
  • [40] Cost-effectiveness of cetuximab, bevacizumab, and panitumumab in first-line treatment of metastatic colorectal cancer (mCRC) for patients with KRAS wild-type (wt) tumors in the United Kingdom
    Samyshkin, Y.
    Hertel, N.
    Griebsch, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345